Studying leukemia stem cell properties and vulnerabilities with human iPSCs

Nikolaos Spyrou\textsuperscript{a,b,c,d}, Eirini P. Papapetrou\textsuperscript{a,b,c,d,*}

\textsuperscript{a}Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
\textsuperscript{b}Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
\textsuperscript{c}Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
\textsuperscript{d}Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Abstract

The reprogramming of cancer cells into induced pluripotent stem cells (iPSCs) can capture entire cancer genomes, and thus create genetically faithful models of human cancers. By providing stringent genetically clonal conditions, iPSC modeling can also unveil non-genetic sources of cancer heterogeneity and provide a unique opportunity to study them separately from genetic sources, as we recently showed in an iPSC-based model of acute myeloid leukemia (AML). Genetically clonal iPSCs, derived from a patient with AML, reproduce, upon hematopoietic differentiation, phenotypic and functional heterogeneity with all the hallmarks of a leukemia stem cell (LSC) hierarchy. Here we discuss the lessons that can be learned about the LSC state, its plasticity, stability and genetic and epigenetic determinants from iPSC modeling. We also discuss the practical and translational implications of exploiting AML-iPSCs to prospectively isolate large numbers of iLSCs for large-scale experiments, such as screens, and for discovery of new therapeutic targets specific to AML LSCs.

1. The concept of AML-LSCs and its clinical relevance

1.1. Cancer stem cells

The cancer stem cell (CSC) model posits that cancers – or at least some of them – are hierarchically organized, with CSCs residing at the apex of this hierarchy. The concept and associated properties of CSCs were formulated as a response to the need to explain two important and nearly universal observations in cancer biology, tumor pathology and clinical reality. The first was that cancers are heterogeneous in many observable ways: histopathologically; in terms of expression of marker genes or cell surface markers; global
gene expression; cellular and molecular phenotypes, such as proliferation and metabolism; and functional readouts, such as the potential to initiate cancer in xenograft models or metastasize. The second observation was that cancers frequently relapse. Thus, concurrently with studies documenting the existence of stem cells in various tissues (tissue-specific or adult stem cells), the idea that cancers are maintained by stem cells, the CSCs, that generate, maintain and can re-establish their heterogeneity, and from which relapse arises, emerged. Since then, the CSC model was refined and still applies to at least some cancers to this day, although the near-universality of this phenomenon has been challenged and more nuance has been overlaid upon the original definitions, in relation to tumor types, context dependencies and variation in frequency of cells with CSC properties (Meacham and Morrison, 2013; Nassar and Blanpain, 2016).

The CSC model endowed CSCs with properties of normal tissue-specific stem cells. Thus CSCs have two defining characteristics: (1) the ability to self-renew and thus re-grow and maintain the cancer; and (2) the ability to give rise to more differentiated cells that themselves cannot initiate or maintain the cancer, thus generating tumor heterogeneity. Following the paradigm of normal tissue-specific stem cells that give rise to a variety of progeny with limited capacity to proliferate, CSCs differentiate into cells that form the bulk of cancer tissue and have limited tumorigenic capacity themselves. This transition is thought to be mediated by epigenetic alterations and to be irreversible or at least rarely reversible.

1.2. Leukemia stem cells

AML LSCs are the prototypical CSCs, as AML was the first malignancy in which a stem cell population could be identified and prospectively isolated (Lapidot et al., 1994; Bonnet and Dick, 1997). AML LSCs share many properties with normal hematopoietic stem cells (HSCs), including self-renewal and multipotency and can initiate and maintain AML by giving rise to identical, as well as more differentiated, daughter cells that cannot propagate the disease. AML LSCs are classically defined by their functional properties in mouse or xenotransplantation models (Lapidot et al., 1994; Bonnet and Dick, 1997; Kreso and Dick, 2014). Seminal work by John Dick’s group in the past two decades established the assays and principles that are now commonly held in this field. Human AML LSCs are typically studied in xenograft models, whereby cells obtained from patients are transplanted into immunodeficient mice, i.e. mice with a compromised immune system that allows them to receive human cell grafts without rejecting them. The definition and properties of LSCs are thus dictated by their observed properties in xenotransplantation assays: self-renewal ability, defined as the ability to give rise to leukemic engraftment that can be maintained over serial transplantation; and differentiation into more mature progeny that, themselves, cannot engraft leukemia (Lapidot et al., 1994; Bonnet and Dick, 1997; Kreso and Dick, 2014).

AML is a hematologic malignancy with a fulminant course and long-term overall survival rates of less than 30% for adults (Dohner et al., 2010). While most patients initially respond to high-dose chemotherapy, many subsequently relapse. Accumulating evidence suggests that patient outcomes, such as overall survival and minimal residual disease after chemotherapy, correlate with measures of LSC activity, such as engraftment in immunodeficient mice and LSC gene expression (van Rhenen et al., 2005; Ran et al., 2009;
PEARCE ET AL., 2006; EPPERT ET AL., 2011; NG ET AL., 2016). LSC frequency and activity in AML have also been associated with chemotherapy resistance and probability of disease relapse (Pollyea and Jordan et al., 2017; Thomas and Majeti, 2017a). Thus, the existence and frequency of LSCs in AML is considered a major determinant of the disease course and response to treatment and therefore understanding the biological properties of LSCs and characterizing their molecular signatures holds promise for developing better therapies.

1.3. Limitations of current xenotransplantation models of AML LSCs

The gold-standard experimental approach to the study of LSCs (and CSCs more broadly) has two components. First, a cell fraction containing the CSCs is prospectively isolated, based on cell surface markers or, more frequently, combinations of markers, typically by fluorescence-activated cell sorting (FACS). This is then transplanted into immunodeficient mice. In the case of AML, leukemic engraftment, detected after a certain length of time in the bone marrow of the recipient mice, means that the transplanted cells contained LSCs, whereas absence of engraftment, and hence, leukemia initiation potential, indicates absence of LSC potential.

However, the very nature of these assays also imposes considerable constraints to the study of LSCs. The first important limitation is the lack of specific and universal cell surface markers to identify, isolate and study AML LSCs, which typically comprise a small fraction of the bulk AML cells. While typically AML LSCs have the CD34+/CD38− immunophenotype, similarly to normal HSCs (Lapidot et al., 1994; Bonnet and Dick, 1997), more recent studies established that LSCs are also contained in the CD34+/CD38+ and even in CD34− cell fractions, especially upon disease progression, while some types of AML are notably CD34− (for example those with NPM1c mutation) (Bonnet and Dick, 1997; Eppert et al., 2011; Ishikawa et al., 2007; Sarry et al., 2011; Ho et al., 2016; Goardon et al., 2011; Pabst et al., 2016; Taussig et al., 2010). As there is no universal marker or combination of markers that can isolate LSCs, markers alone cannot be relied upon to assess LSCs or other CSCs without being combined with xenotransplantation or another functional assay reading out tumor initiation and long-term maintenance. Thus, even though quite widespread, the practice of using marker combinations as surrogates for LSCs can lead to erroneous assumptions and results.

On the other hand, while xenotransplantation is the gold standard for the identification and study of LSCs, the need to functionally define LSCs as cells that reconstitute the disease in immunodeficient mice (Lapidot et al., 1994; Bonnet and Dick, 1997; Kreso and Dick, 2014) adds substantial cost, time and requirement for specialized expertise and is increasingly appreciated to suffer from important drawbacks. Principal amongst them is that engraftment ability has now been shown to be influenced by the host strain and the genetic and clonal composition of the cells, which can both be critical confounding factors to the qualitative and quantitative assessment of LSCs (Klco et al., 2014; Reinisch et al., 2015; Wunderlich et al., 2010). The first xenotransplantation assays used SCID (Lapidot et al., 1994) and later NOD-SCID mice (Bonnet and Dick, 1997). Since then more permissive mouse strains were developed, including the commonly used NOD/SCID/IL2RG−/− (NSG) and NOD/Rag/IL2RG−/− (NRG) mice. Additionally, humanized strains expressing human hematopoietic...
cytokines, such as the NSG-SGM3 mice, constitutively expressing human SCF, GM-CSF and IL-3 (Wunderlich et al., 2010), the MSTGR mice, expressing human M-CSF, TPO, IL3 and GM-CSF (Saito et al., 2016; Rongvaux et al., 2014) and others were developed (Nicolini et al., 2004). Engraftment of patient AML cells and thus the reported frequency of LSCs in different mouse models is variable between studies and influenced by the level of immune deficiency of the host strain (Klco et al., 2014; Goyama et al., 2015). More recent xenograft models using subcutaneous ossicles providing a humanized microenvironment are showing yet higher levels of human AML engraftment (Reinisch et al., 2016). Thus, the choice of mouse model can significantly impact the detection and measured frequency of LSCs.

The LSC – and more generally the CSC – model postulates that cancers are hierarchically organized as a result of non-genetic determinants and that cells with LSC properties exist at a distinct epigenetic state within a genetically homogeneous cancer cell population. In recent years large-scale sequencing of AML genomes provided a much more detailed picture of the mutational landscape of AML and revealed the extent of genetic and clonal heterogeneity present among patients and within the same patient (Cancer Genome Atlas Research et al., 2013; Papaemmanuil et al., 2016). The genetic and clonal composition of a given AML was shown to be a strong determinant of engraftment potential (Klco et al., 2014) with different subclones exhibiting a high degree of variation in their engraftment potential, suggesting that distinct AML genotypes, clones and subclones may differ in their LSC activity and frequency. However the inter-clonal engraftment variation may also be selected by the mouse strain and not be an inherent property of the AML clones. In any case, genetic heterogeneity, which is almost invariably present in AML patient samples, is a significant confounder of LSC studies that is only infrequently accounted for.

Recent experimental evidence is casting some doubts on the clinical relevance of patient-derived xenograft (PDX) readouts, specifically on how well they correlate to patient outcomes. It appears that most xenografts do not recapitulate the clonal architecture of the primary AML and subclones giving rise to clinical relapse do not generally show superior engraftment potential (Klco et al., 2014). Furthermore, the selection forces driving genetic drifts and genetic evolution in PDX models, seem to be different than those acting in patients, leading to increased genomic divergence between the models and the primary leukemia over time (Hussein et al., 2011; Ben-David et al., 2018, 2017). The above collectively raise questions as to how well reading out LSC potential in xenograft assays can inform patient risk and prognosis.

Lastly, xenograft assays, being laborious and costly, are not amenable to high throughput. In vitro or ex vivo models could allow scaling up experiments to expand the capabilities of experimentation to, for example, enable functional genetics, drug testing or genetic and chemical screens. However, such models are practically non-existent. Dick and colleagues reported the derivation of an AML cell line from primary cells that recapitulates their hierarchical organization (Lechman et al., 2016). On the other hand, primary AML LSCs – sorted and retrospectively ascertained after xenotransplants – have very limited ability for ex vivo growth.
2. A new iPSC-based model of AML LSCs

We recently reported a new model of AML LSCs (Wesely et al., 2020; Kotini et al., 2017) (Fig. 1). We derived iPSC lines from a female patient with AML (AML patient 4) through transient ectopic expression of the four Yamanaka factors. The patient’s AML genetics included deletion of chromosome 7q in the context of a complex translocation involving chromosomes 1, 7 and 14, and a subclonal KRAS G12D mutation. The process of reprogramming globally resets the epigenome but maintains the genome intact. Multiple iPSC lines could be derived that contained the genetic lesions of this specific AML, namely the translocation and chromosome 7q loss. Some of them additionally contained the KRAS G12D mutation (Kotini et al., 2017). The AML epigenome was largely erased by the reprogramming process and these AML-iPSCs were indistinguishable from normal human pluripotent stem cells (hPSCs) in terms of phenotype, transcriptome, chromatin and teratoma formation ability (Kotini et al., 2017; Chao et al., 2017).

Upon in vitro differentiation with a protocol yielding primarily definitive-type hematopoiesis through a hemogenic endothelium intermediate, leukemic features were reestablished in the hematopoietic stem/progenitor cells (HSPCs) derived from these AML-iPSC lines. Phenotypically, the AML-iPSC-derived hematopoietic cells exhibited block in their maturation and markedly enhanced proliferation and survival ability, such that CD34+ myeloid cells with immature morphology could be propagated for weeks in culture. Furthermore, these cells recapitulated molecular features of primary AML cells as revealed through transcriptome analyses. Even more remarkably, they were able to engraft NSG mice with high efficiency and serially transplant a lethal leukemia (Wesely et al., 2020; Kotini et al., 2017).

The reprogramming of AML cells generally presents challenges and therefore a very small number of AML-iPSC lines exist today (Kotini et al., 2017; Chao et al., 2017). In comparison to other existing AML-iPSCs generated by us and Chao et al., all lines derived from this patient (with and without the KRAS mutation) exhibited exceptional engraftment capability in NSG mice. This is especially remarkable as blood cells derived from hPSCs are notoriously unable to engraft (Wahlster and Daley, 2016). In fact, AML-iPSC-derived hematopoietic cells are the only example of hematopoietic cells derived from hPSCs through directed in vitro differentiation without ectopic expression of transgenes that can engraft.

Furthermore, we found that hematopoietic cells derived from these “exceptional engrafter” AML-iPSC lines exhibit phenotypic and functional heterogeneity and hierarchical organization, recapitulating an LSC hierarchy. These findings were prompted by the observation that upon differentiation these AML-iPSC lines produced a population of cells with adherent growth that formed a monolayer with cobblestone morphology. Such an adherent cell population is never present in differentiation cultures of iPSC-derived HSPCs. We then found that these adherent cells had the typical immunophenotype of hematopoietic stem cells: CD34+/CD38−/CD90+/CD45RA−/CD49f+ and that they continuously generated in culture daughter cells that grew in suspension as typical hematopoietic cells. Separation of the two cell fractions – adherent and suspension – and replating; sorting and re-culture; and a series of other experiments also involving time-lapse imaging and serial transplantation,

*Stem Cell Res.* Author manuscript; available in PMC 2022 June 10.
showed that these cells exhibit the two cardinal properties of LSCs: ability to self-renew and serially engraft leukemia and to give rise to more differentiated cells. Through a combination of in vitro and in vivo assays we showed that this fraction, that can be readily isolated prospectively by means of adherent in vitro growth, which we called “iLSCs”, resides at the apex of a hierarchy that fulfilled the hallmark features of LSCs: leukemia-initiating activity in vivo in NSG mice, including upon serial transplantation (reading out the property of self-renewal) and re-establishment of heterogeneity in vitro. Several independent lines of inquiry supported the LSC nature of iLSCs. Through serial replating assays, fate tracking at the single-cell level and mathematical modeling approaches we established the presence of a hierarchy whereby iLSCs give rise to more differentiated cells (referred to as “iBlasts”).

We also showed that iLSCs have gene expression and chromatin accessibility signatures of primary human HSCs and LSCs (Eppert et al., 2011; Jaatinen et al., 2006; Gentles et al., 2010). Through integrated genomics analyses of bulk and single-cell transcriptome and chromatin accessibility data we generated a new LSC gene signature. Furthermore, through genome-wide integrative molecular analyses followed by functional validation, we found that iLSCs are dependent on the activity of the transcription factor (TF) RUNX1. We thus identified RUNX1 as a critical regulator sustaining the properties of LSCs and characterized the relevant RUNX1 target genes.

This new model of AML LSCs affords some unique capabilities. First, it enables easy prospective isolation of a cell fraction highly enriched for LSC activity, merely by means of adherence to plastic, without cell sorting. Second, unlike primary AML LSCs, iLSCs can undergo self-renewing divisions in vitro and expand for several days up to a few weeks in culture, reaching numbers of tens or hundreds of millions of cells. Additionally, since the iPSCs they are derived from can be grown indefinitely at the pluripotent state, effectively unlimited numbers of iLSCs can be obtained, enabling for the first time large-scale experiments, including small molecule screens. Our mathematical modeling together with the functional analyses showed that the cellular composition of the system (iBlast/iLSC ratio) is relatively stable over a window of several days following hematopoietic specification, which allows an extended window for experiments, affording some degree of flexibility in its use.

2.1. Lessons for LSC biology

iPSC modeling of human LSCs can aid the study of both LSC biological properties and LSC research towards translational goals.

Is adhesion linked to the LSC state?—One characteristic property of our iLSCs that first alerted us to the presence of heterogeneity in these cultures and prompted us to further investigate its origins, is their adherent growth in tissue culture-treated dishes. In contrast, their more differentiated progeny, the iBlasts, grew in suspension. Although the practical implications of this phenomenon can be harnessed to readily separate the two fractions by means of adherence, the biological implications of these adhesion properties are presently less clear.
Homing and adhesion to the bone marrow (BM) microenvironment niches can be an LSC property beneficial for leukemia initiation and establishment (Konopleva and Jordan, 2011). Links between expression of several adhesion molecules to patient outcomes and LSC activity have been reported and their modulation explored as a potential therapeutic avenue (Rombouts et al., 2004). These include integrins, such as VLA-4 and CD44, selectins, and the CXCL12 (SDF-1)/CXCR4 chemokine receptor axis, which may also cross-talk with integrins. A monoclonal antibody against CD44 was shown to eradicate AML LSCs in xenograft mice (Jin et al., 2006). Neutralizing CXCR4 antibodies prevented both homing and leukemia initiation of primary human AML cells, as well as their long-term maintenance in xenograft recipients, while the same treatment did not affect the engraftment of normal HSCs (Tavor et al., 2004). Inhibiting adhesion mediated by VLA-4 and CXCR-4 has been proposed as a means to overcome chemotherapy resistance and relapse by mobilizing LSCs out of the BM niches (Matsunaga et al., 2003, 2008; Zeng et al., 2006, 2009; Fierro et al., 2009).

While in vivo homing and adhesion to BM niches involves complex interactions, adherence to regular tissue culture-treated dishes in culture is primarily mediated by integrins binding to extracellular matrix, while selectins and other adhesion molecules are typically involved in cell–cell interactions. We found that enforced detachment to prevent adherent growth did not affect iLSC properties, such as immunophenotype and engraftment potential, in our study (Wesely et al., 2020). Furthermore, iLSCs and iBlasts had comparable in vivo homing ability and other AML-iPSC-derived LSCs do not possess enhanced adherence properties in tissue culture (Chao et al., 2017). These observations, taken together, do not support a direct link between homing, adhesion and LSC function. It is still, however, possible that common regulators of adhesion and the LSC state play a role in endowing cells with LSC activity.

**Is the LSC state reversible?**—To thoroughly characterize the hierarchical relationships within the iLSC cultures, we employed a combination of mixed culture and sort-and-reculture experiments; mathematical modeling; single-cell plating and fate-tracking; and time-lapse imaging experiments (Wesely et al., 2020). These showed that, even though the hierarchical relationship was overwhelmingly in the direction of iLSCs (adherent cells) giving rise to iBlasts (suspension cells), a low-rate reversion of iBlasts to iLSCs could not be excluded. While it is possible that imperfect separation of iBlasts and iLSCs may confound this conclusion and, also, importantly, our calculations are constrained by the assumptions of the Markovian mathematical modeling approach we used, there are precedents for a bidirectional relationship between solid tumor CSCs and their more mature derivatives (Meacham and Morrison, 2013; Gupta et al., 2019).

Conversion of transformed human mammary epithelial cells into CSC-like cells has been described, albeit in a tissue in which non-malignant differentiated cells can spontaneously dedifferentiate into stem-like cells (Chaffer et al., 2011; Gupta et al., 2011). Additional examples of acquisition of stem cell-like properties and de novo generation of CSC-like cells from more differentiated non-CSCs in other epithelial tissues, sometimes in response to external stimuli, exist, mostly in mouse models (Schwitalla et al., 2013). Although such bidirectional conversion has not been documented in AML or normal hematopoiesis, the classic hematopoietic hierarchy is increasingly now found to be less rigid than previously...
thought (Eaves, 2015). It is possible that the LSC state is more plastic and dynamic than previously appreciated and that this may furthermore be influenced by cell-intrinsic factors, stochasticity, microenvironmental factors, as well as drug exposures.

**Will all AML-iPSCs exhibit an LSC population?**—Another important question that remains unanswered is the generalizability of this iLSC population in other AML-iPSC lines derived from other patients and other AML genotypes. The lines we analyzed were all derived from one AML patient harboring a complex translocation resulting in loss of chromosome 7q (Kotini et al., 2017). The same iLSC population was observed in multiple iPSC lines derived from this patient, including iPSC lines derived from a subclone of the patient’s leukemia, harboring an additional KRAS G12D mutation, in addition to the translocation (Kotini et al., 2017). These lines exhibited exceptionally high engraftment potential in NSG mice, serially transplanted a lethal leukemia and could be propagated long-term in vitro as immature CD34+ cells (Kotini et al., 2017). We have not observed this combination of properties in any of the few currently existing AML-iPSC lines (Kotini et al., 2017; Chao et al., 2017). Thus, it is currently unclear whether an in vitro self-renewing LSC/CSC population will be found upon differentiation of other AML-iPSC lines and iPSCs from other types of cancers and whether, if it is found, it will similarly exhibit high in vitro adhesion properties.

Because reprogramming of AML cells and primary cancer cells from solid tumors is technically challenging (Papapetrou, 2016a, 2019a, 2019b), very few such iPSC lines currently exist, and several more tumor cells will need to be reprogrammed in the future before this question can be answered conclusively.

**What is the impact of reprogramming on the iLSC state?**—A very interesting question that is related to the question above is whether the iLSC properties that we observed are impacted or even endowed by the process of reprogramming itself. Indeed, iLSCs appear to be even more potent in terms of leukemia initiating ability and in vitro self-renewal than primary AML LSCs. Reprogramming to a pluripotent state causes a massive resetting of the chromatin and epigenetic properties of the starting cell to the extent that it is effectively a “naked” genome of the starting cell that is captured in an iPSC, which has now become largely agnostic to its cellular origins (Papapetrou, 2016a, 2016b). We and others showed that AML cells reprogrammed into iPSCs exhibit no overt cellular or molecular malignant features at the pluripotent state (Kotini et al., 2017; Chao et al., 2017). It is only upon specification of the hematopoietic lineage that leukemic properties are re-established (Kotini et al., 2017; Chao et al., 2017). This constitutes clear evidence that, first, a specific cellular milieu is necessary for LSC properties to manifest and, second, that the AML genome alone is sufficient to re-establish leukemic properties upon exposure to the appropriate cellular environment. The processes of reprogramming and differentiation are both accompanied by dramatic genome-wide changes in accessible chromatin, histone marks and chromatin architecture (Papp and Plath, 2013; Apostolou and Hochedlinger, 2013; Hochedlinger and Jaenisch, 2015) and are, essentially, processes moving in opposite directions, with reprogramming erasing somatic cell epigenetic characteristics and in vitro directed differentiation establishing hematopoietic cell fate-specific chromatin marks and
gene expression programs. Reprogramming to pluripotency can reverse features associated with cellular aging, such as telomere length, mitochondrial and nuclear morphology, heterochromatin marks and gene expression profiles (Mahmoudi et al., 2019).

There are still only limited data from studies comparing the starting somatic cells to the matched iPSC-derived cell types and these have revealed both striking similarities, as well as some differences (Handel et al., 2016; Volpato and Webber, 2020). The latter may be related to the in vitro culture, the reprogramming and/or the developmental stage captured upon differentiation. Protocols of iPSC differentiation mimic development and coax the cells, through exposure to growth factors and morphogens, to exit pluripotency and commit gradually to a germ cell layer and a tissue-specific progenitor lineage. There is ample evidence that iPSC-derived cell types are characterized by a certain degree of developmental immaturity (Zeltner and Studer, 2015). Specifically, hematopoietic cells derived from iPSCs more closely resemble fetal than adult-type hematopoietic stem and progenitor cells (Ditadi et al., 2017; Lacaud and Kouskoff, 2017; Ivanovs et al., 2017). Notably, fetal liver hematopoietic stem/progenitor cells are characterized by remarkable proliferation and expansion properties. Thus it is possible, although it remains speculative, that the potent “stemness” of iLSCs is at least in part endowed or unleashed by the reprogramming and/or differentiation processes themselves by means that may involve “rejuvenation” or activation of fetal hematopoiesis programs. However, it should also be noted here, that reprogramming and re-differentiation of normal hematopoietic cells typically yields hematopoietic progenitors with more limited proliferation capacity than primary hematopoietic progenitor cells. Thus, the effects, if any, of the reprogramming and differentiation processes in increasing self-renewal of AML cells must be somehow specific to a leukemic context.

**Can iLSCs inform the generation of normal engraftable hPSC-derived hematopoiesis?**—The lack of engraftment of hPSC-derived hematopoiesis presents a major roadblock for both disease modeling and cell therapy applications of stem cell research. Despite intense research efforts over the years, the consistent and efficient generation or long-term repopulating HSCs with multilineage reconstitution potential from hPSCs is still elusive (Vo and De Daley, 2015; Papapetrou and Sadelain, 2010). While the reasons for this are not entirely clear, it seems to be a limitation of current differentiation protocols and not due to a lack of HSC potential by hPSCs, as HSCs with long-term repopulating capability can be generated in vivo from human iPSC-derived teratomas (Amabile et al., 2013; Suzuki et al., 2013). Despite our incomplete understanding of the nature of the problem, it is almost certain that a better understanding of the gene regulatory networks that sustain self-renewal of HSCs is needed to guide improvements in methods for producing HSCs from hPSCs. It is thus remarkable that AML-iPSC-derived hematopoietic cells can engraft so efficiently. This is currently the only case of robust, high-level, long-term engraftment of hematopoietic cells derived from any type of hPSC solely through directed differentiation without the forced expression of transcription factors or other exogenous factors (Kotini et al., 2017; Chao et al., 2017). iLSCs may thus provide a unique opportunity and a valuable tool to investigate the engraftment requirements of hPSC-derived cells and apply this knowledge towards the generation of engraftable HSPCs from normal hPSCs. It is possible, even though speculative at the moment, that the iLSCs may be
capturing a pre-HSC state that transiently emerges during hPSC directed differentiation and is rendered self-propagating and thus observable through an effect of the leukemic genome in enhancing the self-renewal of this cell state. While heavily myeloid-biased, these AML-iPSC lines could generate other lineages, such as erythroid, megakaryocytic (in vitro) and B lymphocytes (in vivo) (Kotini et al., 2017). Our study of iLSCs with integrated genomics approaches nominated several putative regulators of engraftable hematopoiesis that can be tested in future studies.

2.2. Opportunities for therapeutic targeting of AML LSCs

The therapeutic premise of the CSC model lies in the presumption that CSCs are the main source of cancer resistance and relapse. It is further assumed that CSCs are generally chemoresistant and that most current chemotherapies and targeted therapies do not target CSCs. CSCs are thought to have distinct biological properties than the bulk cells of a tumor that make them resistant to most conventional therapies, but some of which may create specific vulnerabilities that may offer opportunities for therapeutic targeting. Such therapies specifically targeting CSCs hold the promise of improved long-term outcomes or even cures. Better characterization of the distinct molecular circuitries that sustain CSCs could thus pinpoint new therapeutic targets specific to CSCs.

Separating genetic from non-genetic sources of tumor heterogeneity.—

Heterogeneity that can be explained by the LSC model is strictly and necessarily non-genetic. The premise of the LSC model, as originally articulated in the 1990s, and of the CSC model more generally, is that cancers are hierarchically organized as a result of non-genetic determinants and that cells with LSC properties exist at a distinct epigenetic state within a genetically homogeneous cancer cell population (Dick, 2008). However, it is now apparent that genetic heterogeneity is an important source of heterogeneity, confounding the LSC model of non-genetic heterogeneity and the study of LSC properties (Kreso and Dick, 2014; Shackleton et al., 2009). Most LSC and CSC studies do not account for genetic heterogeneity, which makes claims on non-genetic sources of heterogeneity difficult to conclusively ascertain. By uniquely offering genetically clonal conditions, our iLSC model unequivocally lends support to the LSC model, as a source of non-genetic heterogeneity. Furthermore, it offers the opportunity to disentangle genetic from non-genetic contributions to phenotypic, epigenetic and functional heterogeneity. Different AML genetic clones are likely to differ in their LSC potential and frequency. PDX studies have revealed that different AML genotypes and subclones exhibit a high degree of variation in their engraftment potential (Klco et al., 2014). Furthermore, a recent seminal study by the Dick lab showed that the AML genotype can impact the LSC hierarchy, with some AML types exhibiting more “shallow” or “deep” hierarchies (Shlush et al., 2017). The future generation of AML-iPSCs from diverse AML genotypes capturing different genetic groups, clones and subclones, can help better characterize the contribution of genetics to the LSC hierarchy.

LSC gene signatures.—The clear associations of LSC frequency with clinical outcomes in AML patients and the impracticality of assessing LSC activity functionally in the clinical setting led several efforts to derive LSC gene expression signatures that can be used as surrogate measures of LSC activity (Eppert et al., 2011; Ng et al., 2016; Lechman et al.,
Gentles et al. derived a 52-gene LSC signature by sorting CD34+/CD38− cells from AML patient cells (without functional validation) and microarray gene expression analysis (Gentles et al., 2010). Another research group integrated DNA methylation with gene expression to derive a 71-gene LSC epigenetic signature using xenotransplantation-validated AML LSCs and identified the HOXA cluster as a key regulator of the LSC state (Jung et al., 2015). Ng et al. derived a 17-gene LSC gene signature (LSC17) from xenotransplantation-validated LSC-enriched populations using a statistical regression algorithm. The LSC17 score was prognostic of therapeutic resistance and overall survival in independent patient cohorts of diverse AML genetic groups (Ng et al., 2016). This LSC17 score or scores of subsets of the 17 genes were also shown to be predictive of prognosis in pediatric AML and MDS patient cohorts (Duployez et al., 2019; Wang et al., 2020). Among the 17 genes, GPR56, has also been independently identified as a AML LSC marker gene (Pabst et al., 2016). The same group has also generated a microRNA (miRNA) AML LSC signature from functionally validated LSC populations of AML patients and identified a role for a specific miRNA, miR-126, in LSC quiescence and self-renewal (Lechman et al., 2016). In our study, by integrating transcriptomic (RNA-Seq) and chromatin accessibility (ATAC-Seq) data, comparing the iLSCs to their genetically identical more mature progeny (iBlasts), we derived a 42-gene signature. This was further refined to a set of 16 genes that were non-overlapping with the LSC17 score and could predict survival in two independent AML patient cohorts (Wesely et al., 2020).

LSC signatures are limited by the degree of purity of LSC isolation. As stated earlier, no marker or combination thereof can isolate LSCs to a high degree of purity. Since the iLSCs in our study appear to be highly enriched for LSC activity, it is possible that the iLSC gene signature may capture a more faithful LSC program, but this still remains to be tested.

Upregulation of early hematopoiesis programs and Homeobox family genes were recurring themes observed in the various LSC signatures discussed above. Furthermore, some of these studies, including ours, showed that LSC gene signatures are predictive of disease outcomes across AML genetic groups, consistent with measures of LSC activity being an independent prognostic factor, although this requires further investigation. It still remains to be seen how useful such LSC signatures will be in the clinic, how they correlate to different genetic groups, especially those clearly associated with adverse or favorable prognosis, and whether they will provide additional prognostic information over currently used schemes to aid better classification and prognostication for AML patients. On the other hand, the various LSC gene sets, derived from transcriptomics, chromatin accessibility, miRNA or DNA methylation datasets, nominate new genes with a role in LSCs and can thus lead to new hypotheses and open new lines of investigation, as our study and other studies mentioned here, have highlighted (Pabst et al., 2016; Lechman et al., 2016; Wesely et al., 2020; Jung et al., 2015).

**New LSC targets.**—The importance of the LSC model in the clinic lies in the hypothesis that LSCs must be eradicated for long-lasting remission and that it should be theoretically possible to exploit specific vulnerabilities to uncover therapeutic targets. LSCs are believed to have properties distinct from those of the bulk AML cells that may provide opportunities to develop therapies that are targeted specifically against LSCs. Cellular properties, such as...
drug efflux, DNA damage response and quiescence, may underlie chemoresistance of LSCs and at the same time provide new targetable vulnerabilities. LSCs have been shown to be quiescent and less susceptible to chemotherapy (Pollyea and Jordan, 2017; Ishikawa et al., 2007; Guzman et al., 2001; Guan et al., 2003; Hope et al., 2004; Terpstra et al., 1996; Saito et al., 2010). However, contradictory evidence also exists for the existence of cycling LSC populations with sensitivity to cytarabine similar to that of the bulk blasts, suggesting that these may not be universal properties of all AML LSCs (Eppert et al., 2011; Pollyea and Jordan, 2017; Sarry et al., 2011; Ho et al., 2016; Iwasaki et al., 2015). Metabolic and signaling dependencies have been proposed to potentially distinguish LSCs from the bulk of AML cells (Pollyea and Jordan, 2017; Thomas and Majeti, 2017b). These include oxidative phosphorylation, fatty acid oxidation, glutathione metabolism, mitochondrial activity, the unfolded protein response, heat shock protein response, WNT/β-catenin, NOTCH, Hedgehog and NF-κB pathway activation (Guzman et al., 2001, 2002, 2005; Lagadinou et al., 2013; Ye et al., 2016; Zong et al., 2015; Kagoya et al., 2014; Pei et al., 2013; Skrtic et al., 2011). Epigenetic dependencies of LSCs, such as DOT1L and LSD1 inhibition, have been proposed, especially for MLL-rearranged AML (Bernt et al., 2011; Harris et al., 2012; Schenk et al., 2012). Some therapies that are currently in development and proposed to target LSCs include Bcl-2 inhibitors, DOT1L and LSD1 inhibitors and BET inhibitors (Pollyea and Jordan, 2017; Lagadinou et al., 2013; Bernt et al., 2011; Harris et al., 2012; Schenk et al., 2012; Fong et al., 2015).

Cell surface markers that could distinguish LSCs from the bulk AML and from normal HSCs are highly desirable and currently an area of intense investigation. Such markers could be valuable as they could provide biomarkers to monitor response to therapy and predict relapse; targets for antibody-based (toxin-conjugated or eliciting cell-mediated toxicity) or CAR T-cell-based therapies; as well as a means of purifying LSCs for study. LSCs are generally enriched within the CD34+/CD38− fraction, although it is now clear that other fractions contain LSCs as well (Bonnet and Dick, 1997; Eppert et al., 2011; Ishikawa et al., 2007; Sarry et al., 2011; Ho et al., 2016; Goardon et al., 2011). The interleukin-3 receptor α CD123 was the first marker proposed as a LSC specific antigen and a toxin-conjugated antibody against it is currently tested in clinical trials (Jordan et al., 2000). Other antigens currently tested in clinical trials as LSC specific targets are CD47 and CD33 (Taussig et al., 2005; Theocharides et al., 2012; Walter et al., 2012). CD99 and TIM3 are some more recent candidates (Jan et al., 2011; Chung et al., 2017). However none of these are exclusive or universal LSC markers and high variation in their expression has been observed between patients, within the same patient, as well as pre- and post- treatment (Pollyea and Jordan, 2017; Thomas and Majeti, 2017b).

Our iLSC study revealed dependence on the RUNX1 TF as a vulnerability of LSCs. By characterizing the relevant RUNX1 target genes, we discovered that TSPAN18 (Tetraspanin 18) at least partially mediates the RUNX1 effects in iLSCs. As a cell surface protein, Tetraspanin 18, can function both as a marker for purification, as well as a target for antibody or CAR-based approaches. Tetraspanins have diverse roles in membrane organization and compartmentalization, but also in cell signaling (Hemler, 2005). Other members of the tetraspanin family have previously been proposed to play roles in AML LSCs (Kwon et al., 2015; Vetrie et al., 2020; de Boer et al., 2018). The iLSC model could be

*Stem Cell Res.* Author manuscript; available in PMC 2022 June 10.
used to uncover and validate additional targetable genes, pathways or cellular processes specific to LSCs, although it still remains to be seen if any will sufficiently distinguish between LSCs and the bulk AML cells, as well as normal HSCs for a favorable toxicity profile.

The role of RUNX1 as tumor suppressor and oncogene.—Our analyses, integrating bulk RNA-Seq, single-cell RNA-Seq, ATAC-Seq and CHIP-Seq data, combined with RUNX1 knockdown (KD), zeroed in on RUNX1, as a critical TF for iLSCs. This was validated by functional experiments, showing that iLSCs, but not their differentiated progeny, the iBlasts, are dependent on RUNX1, since RUNX1 reduction by 50% abolished their leukemia initiating ability in vivo and led to their exhaustion in vitro (Wesely et al., 2020). By knocking down RUNX1 in primary AML samples we showed the generalizability of RUNX1 dependency across genetic subtypes of AML in vitro and in vivo. We did not find evidence for preferential RUNX1 dependency or lack thereof in association with any specific genetic group, but rather found that vulnerability to RUNX1 KD is determined by the LSC frequency (CD34+ fraction), consistent with the idea that RUNX1 is an LSC-specific dependency. We also derived a RUNX1-dependent LSC gene signature consisting of 20 target genes activated by RUNX1 (down after KD) and 47 genes repressed by RUNX1 (up after KD). This RUNX1-LSC signature correlated with patient survival and RUNX1 expression in AML patients (Wesely et al., 2020).

RUNX1 is a key transcriptional regulator of the hematopoietic system during development and the endothelial-to-hematopoietic transition (Gao et al., 2018; Chen et al., 2009). RUNX1, also known as acute myeloid leukemia 1 protein, AML1, has well-known tumor suppressor roles in AML. It is often translocated in sporadic AML and is the target of somatic and germline loss-of-function or dominant negative mutations, causing familial predisposition to AML (RUNX1-familial platelet disorder, FPD) (Song et al., 1999; Hatlen et al., 2012; Sood et al., 2017). On the other hand, a requirement for wild-type RUNX1 has been proposed in some types of AML, namely those harboring RUNX1 translocations, MLL translocations or FLT3-ITD mutations (Sood et al., 2017; Goyama et al., 2013) and an oncogenic role of RUNX1 in cooperation with FLT3-ITD has also been reported in a mouse model of AML (Behrens et al., 2017). Our results, implicating RUNX1 in LSC maintenance, can provide a mechanistic explanation for previous findings correlating high RUNX1 expression in AML patients with worse survival (Fu et al., 2016), a correlation that we also found in our analyses of independent AML patient cohorts (Wesely et al., 2020).

It is intriguing and somewhat paradoxical that RUNX1 haploinsufficiency or loss of function is an AML- initiating and promoting event and at the same time high RUNX1 levels are required for LSCs once AML is established, as haploinsufficiency for RUNX1 led to loss of LSCs over time (Wesely et al., 2020). There are several studies suggesting that RUNX1 dosage may be critical and that its levels need to be maintained within a certain range (Morita et al., 2017; Mill et al., 2019; Batcha et al., 2019; Antony-Debre et al., 2015). It is also possible that RUNX1 plays different roles at different stages during AML development, as it does during different stages in the development of the hematopoietic system. Very likely this TF holds more secrets that future studies will need to uncover. Before a better understanding of the role RUNX1 plays in different cellular contexts, ranging from normal,
pre-malignant and malignant hematopoietic cells can be attained, our findings suggest that approaches aimed at restoring RUNX1 expression in familial and sporadic cases of RUNX1-mutated AML should proceed with caution.

3. Concluding remarks

Even though the rationale for targeting LSCs to achieve long-lasting remissions or cures remains to be proven, targeting LSCs is a highly desirable goal of translational AML research. iPSC-derived LSC models offer new opportunities to understand the biological properties of LSCs, their dependencies on different AML genotypes and the exciting prospect of performing high-throughput genetic screens, such as CRISPR knockout screens, or small molecule screens of libraries of compounds.

Acknowledgements

This work was supported by the US National Institutes of Health (NIH) grants R01HL137219 and R01CA225231, by the New York State Stem Cell Board, the Pershing Square Sohn Cancer Research Alliance, the RUNX1 Research Program (RRP)/Alex’s Lemonade Stand Foundation (ALSF) and by a Scholar award from the Leukemia and Lymphoma Society.

References

Amabile G, et al., 2013. In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells. Blood 121, 1255–1264. 10.1182/blood-2012-06-434407. [PubMed: 23212524]

Antony-Debre I, et al., 2015. Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia. Blood 125, 930–940. 10.1182/blood-2014-06-585513. [PubMed: 25490895]

Apostolou E, Hochedlinger K, 2013. Chromatin dynamics during cellular reprogramming. Nature 502, 462–471. 10.1038/nature12749. [PubMed: 24153299]

Batcha AMN, et al., 2019. Allelic imbalance of recurrently mutated genes in acute myeloid leukemia. Sci. Rep 9, 11796. 10.1038/s41598-019-48167-4. [PubMed: 31409822]

Behrens K, et al., 2017. RUNX1 cooperates with FLT3-ITD to induce leukemia. J. Exp. Med 214, 737–752. 10.1084/jem.20160927. [PubMed: 28213513]

Ben-David U, et al., 2017. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat. Genet 49, 1567–1575. 10.1038/ng.3967. [PubMed: 28991255]

Ben-David U, et al., 2018. Genetic and transcriptional evolution alters cancer cell line drug response. Nature 560, 325–330. 10.1038/s41586-018-0409-3. [PubMed: 30089904]

Bernt KM, et al., 2011. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66–78. 10.1016/j.ccr.2011.06.010. [PubMed: 21741597]

Bonnet D, Dick JE, 1997. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med 3, 730–737. [PubMed: 9212098]

Cancer Genome Atlas Research, N., et al., 2013. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med 368, 2059–2074. doi:10.1056/NEJMoa1301689. [PubMed: 23634996]

Chaffer CL, et al., 2011. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. U.S.A 108, 7950–7955. 10.1073/pnas.1102454108. [PubMed: 21498687]

Chao MP, et al., 2017. Human AML-iPSCs reacquire leukemic properties after differentiation and model clonal variation of disease. Cell Stem Cell 20, 329–344 e327. doi:10.1016/j.stem.2016.11.018. [PubMed: 28089908]
Chen MJ, Yokomizo T, Zeigler BM, Dzierzak E, Speck NA, 2009. Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. Nature 457, 887–891. 10.1038/nature07619. [PubMed: 19129762]

Chung SS, et al., 2017. CD99 is a therapeutic target on disease stem cells in myeloid malignancies. Sci. Transl. Med 9 10.1126/scitranslmed.aaj2025.

de Boer B, et al., 2018. Prospective isolation and characterization of genetically and functionally distinct AML subclones. Cancer Cell 34, 674–689 e678. doi:10.1016/j.ccell.2018.08.014. [PubMed: 30245083]

Dick JE, 2008. Stem cell concepts renew cancer research. Blood 112, 4793–4807. 10.1182/blood-2008-08-177941. [PubMed: 19064739]

Ditadi A, Sturgeon CM, Keller G, 2017. A view of human haematopoietic development from the Petri dish. Nat. Rev. Mol. Cell Biol 18, 56–67. 10.1038/nrm.2016.127. [PubMed: 27876786]

Dohner H, et al., 2010. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115, 453–474. 10.1182/blood-2009-07-235358. [PubMed: 19880497]

Duployez N, et al., 2019. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. Leukemia 33, 348–357. 10.1038/s41375-018-0227-5. [PubMed: 30089916]

Eaves CJ, 2015. Hematopoietic stem cells: concepts, definitions, and the new reality. Blood 125, 2605–2613. 10.1182/blood-2014-12-570200. [PubMed: 25762175]

Eppert K, et al., 2011. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med 17, 1086–1093. 10.1038/nmm.2415. [PubMed: 21879988]

Fierro FA, et al., 2009. Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia. Leukemia 23, 393–396. 10.1038/leu.2008.182. [PubMed: 18615106]

Fong CY, et al., 2015. BET inhibitor resistance emerges from leukaemia stem cells. Nature 525, 538–542. 10.1038/nature14888. [PubMed: 26367796]

Fu L, et al., 2016. High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia. Oncotarget 7, 15828–15839. 10.18632/oncotarget.7489. [PubMed: 26910834]

Gao L, et al., 2018. RUNX1 and the endothelial origin of blood. Exp. Hematol 10.1016/j.exphem.2018.10.009.

Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA, 2010. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 304, 2706–2715. 10.1001/jama.2010.1862. [PubMed: 21177505]

Goardon N, et al., 2011. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19, 138–152. 10.1016/j.ccr.2010.12.012. [PubMed: 21251617]

Goyama S, et al., 2013. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J. Clin. Invest 123, 3876–3888. 10.1172/JCI68557. [PubMed: 23979164]

Goyama S, Wunderlich M, Mulloy JC, 2015. Xenograft models for normal and malignant stem cells. Blood 125, 2630–2640. 10.1182/blood-2014-11-570218. [PubMed: 25762176]

Guan Y, Gerhard B, Hogge DE, 2003. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 101, 3142–3149. 10.1182/blood-2002-10-3062. [PubMed: 12468427]

Gupta PB, et al., 2011. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146, 633–644. 10.1016/j.cell.2011.07.026. [PubMed: 21854987]

Gupta PB, Pastushenko I, Skibinski A, Blanpain C, Kuperwasser C, 2019. Phenotypic plasticity: driver of cancer initiation, progression, and therapy resistance. Cell Stem Cell 24, 65–78. 10.1016/j.stem.2018.11.011. [PubMed: 30554963]

Guzman ML, et al., 2001. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98, 2301–2307. [PubMed: 11588023]

Guzman ML, et al., 2002. Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl. Acad. Sci. U.S.A 99, 16220–16225. 10.1073/pnas.252462599. [PubMed: 12451177]
Guzman ML, et al., 2005. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105, 4163–4169. 10.1182/blood-2004-10-4135. [PubMed: 15687234]

Handel AE, et al., 2016. Assessing similarity to primary tissue and cortical layer identity in induced pluripotent stem cell-derived cortical neurons through single-cell transcriptomics. Hum. Mol. Genet 25, 989–1000. 10.1093/hmg/ddv637. [PubMed: 26740550]

Harris WJ, et al., 2012. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AP9 leukemia stem cells. Cancer Cell 21, 473–487. 10.1016/j.ccr.2012.03.014. [PubMed: 22464800]

Hatlen MA, Wang L, Nimer SD, 2012. AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches. Front. Med 6, 248–262. 10.1007/s11684-012-0206-6. [PubMed: 22875638]

Hemler ME, 2005. Tetraspanin functions and associated microdomains. Nat. Rev. Mol. Cell Biol 6, 801–811. 10.1038/nrm1736. [PubMed: 16314869]

Ho TC, et al., 2016. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood 128, 1671–1678. 10.1182/blood-2016-02-695312. [PubMed: 27421961]

Hochdillinger K, Jaenisch R, 2015. Induced pluripotency and epigenetic reprogramming. Cold Spring Harb. Perspect. Biol 7. 10.1101/cshperspect.a019448.

Hope KJ, Jin L, Dick JE, 2004. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol 5, 738–743. 10.1038/ni1080. [PubMed: 15170211]

Hussein SM, et al., 2011. Copy number variation and selection during reprogramming to pluripotency. Nature 471, 58–62. 10.1038/nature09871. [PubMed: 21368824]

Ishikawa F, et al., 2007. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol 25, 1315–1321. 10.1038/nbt1350. [PubMed: 17952057]

Ivanova S, et al., 2017. Human haematopoietic stem cell development: from the embryo to the dish. Development 144, 2323–2337. 10.1242/dev.134866. [PubMed: 28676567]

Iwasaki M, Liedtke M, Gentles AJ, Cleary ML, 2015. CD93 marks a non-quiescent human leukemia stem cell population and is required for development of MLL-rearranged acute myeloid leukemia. Cell Stem Cell 17, 412–421. 10.1016/j.stem.2015.08.008. [PubMed: 2637756]

Jaatinen T, et al., 2006. Global gene expression profile of human cord blood-derived CD133+ cells. Stem Cells 24, 631–641. 10.1634/stemcells.2005-0185. [PubMed: 16210406]

Jan M, et al., 2011. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc. Natl. Acad. Sci. U.S.A 108, 5009–5014. 10.1073/pnas.1100551108. [PubMed: 21383193]

Jin L, Hope KJ, Zhao Q, Smadja-Joffe F, Dick JE, 2006. Targeting of CD44 eradicates human acute myeloid leukemia stem cells. Nat. Med 12, 1167–1174. 10.1038/nm1483. [PubMed: 16998484]

Jordan CT, et al., 2000. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14, 1777–1784. [PubMed: 11021753]

Jung N, Dai B, Gentles AJ, Majeti R, Feinberg AP, 2015. An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis. Nat. Commun 6, 8489. 10.1038/ncomms9489. [PubMed: 26444494]

Kagoya Y, et al., 2014. Positive feedback between NF-kappaB and TNF-alpha promotes leukemia-initiating cell self-renewal capacity. J. Clin. Invest 124, 528–542. 10.1172/JCI68101. [PubMed: 24382349]

Klco JM, et al., 2014. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 25, 379–392. 10.1016/j.ccr.2014.01.031. [PubMed: 24613412]

Konopleva MY, Jordan CT, 2011. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J. Clin. Oncol 29, 591–599. 10.1200/JCO.2010.31.0904. [PubMed: 21220598]

Kotini AG, et al., 2017. Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia. Cell Stem Cell 10.1016/j.stem.2017.01.009. [PubMed: 28215825]

doi:10.1016/j.stem.2017.01.009 [PubMed: 28215825]
Kreso A, Dick JE, 2014. Evolution of the cancer stem cell model. Cell Stem Cell 14, 275–291. 10.1016/j.stem.2014.02.006. [PubMed: 24607403]

Kwon HY, et al., 2015. Tetraspanin 3 is required for the development and propagation of acute myelogenous leukemia. Cell Stem Cell 17, 152–164. 10.1016/j.stem.2015.06.006. [PubMed: 26212080]

Lacaud G, Kouskoff V, 2017. Hemangioblast, hemogenic endothelium, and primitive versus definitive hematopoiesis. Exp. Hematol 49, 19–24. 10.1016/j.exphem.2016.12.009. [PubMed: 28043822]

Lagadinou ED, et al., 2013. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12, 329–341. 10.1016/j.stem.2012.12.013. [PubMed: 23333149]

Lapidot T, et al., 1994. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645–648. 10.1038/367645a0. [PubMed: 7509044]

Lechman ER, et al., 2016. miR-126 regulates distinct self-renewal outcomes in normal and malignant hematopoietic stem cells. Cancer Cell 29, 602–606. 10.1016/j.ccell.2016.03.015. [PubMed: 27070706]

Mahmoudi S, Xu L, Brunet A, 2019. Turning back time with emerging rejuvenation strategies. Nat. Cell Biol 21, 32–43. 10.1038/s41556-018-0206-0. [PubMed: 30602763]

Matsunaga T, et al., 2003. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med 9, 1158–1165. 10.1038/nm909. [PubMed: 12897778]

Matsunaga T, et al., 2008. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Leukemia 22, 353–360. 10.1038/sj.leu.2405017. [PubMed: 17972943]

Meacham CE, Morrison SJ, 2013. Tumour heterogeneity and cancer cell plasticity. Nature 501, 328–337. 10.1038/nature12624. [PubMed: 24048065]

Mill CP, et al., 2019. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood 134, 59–73. 10.1182/blood.2018893982. [PubMed: 31023702]

Morita K, et al., 2017. Paradoxical enhancement of leukemogenesis in acute myeloid leukemia with moderately attenuated RUNX1 expressions. Blood Adv. 1, 1440–1451. 10.1182/bloodadvances.2017007591. [PubMed: 29296785]

Nassar D, Blanpain C, 2016. Cancer stem cells: basic concepts and therapeutic implications. Annu. Rev. Pathol 11, 47–76. 10.1146/annurev-pathol-012615-044438. [PubMed: 27193450]

Ng SW, et al., 2016. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 540, 433–437. 10.1038/nature20598. [PubMed: 27926740]

Nicolini FE, Cashman JD, Hogge DE, Humphries RK, Eaves CJ, 2004. NOD/SCID mice engineered to express human IL-3, GM-CSF and steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration. Leukemia 18, 341–347. 10.1038/sj.leu.2403222. [PubMed: 14628073]

Papapetrou EP, 2016b. Induced pluripotent stem cells, past and future. Science 353, 991–992. 10.1126/science.aai7626. [PubMed: 27701103]

Papaemmanuil E, et al., 2016. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med 374, 2209–2221. 10.1056/NEJMoa1516192. [PubMed: 27276561]

Papapetrou EP, 2016a. Patient-derived induced pluripotent stem cells in cancer research and precision oncology. Nat. Med 22, 1392–1401. 10.1038/nm.4238. [PubMed: 27923030]

Papapetrou EP, 2016b. Induced pluripotent stem cells, past and future. Science 353, 991–992. 10.1126/science.aai7626. [PubMed: 27701103]

Papapetrou EP, 2019a. Modeling myeloid malignancies with patient-derived iPSCs. Exp. Hematol 71, 77–84. 10.1016/j.exphem.2018.11.006. [PubMed: 30481543]

Papapetrou EP, 2019b. Modeling leukemia with human induced pluripotent stem cells. Cold Spring Harb. Perspect. Med 9 10.1101/cshperspect.a034868.

Papapetrou EP, Sadelain M, 2010. Reconstructing blood from induced pluripotent stem cells. F1000 Med. Rep 2. doi:10.3410/M2-44.
Papp B, Plath K, 2013. Epigenetics of reprogramming to induced pluripotency. Cell 152, 1324–1343. 10.1016/j.cell.2013.02.043. [PubMed: 23498940]

Pearce DJ, et al., 2006. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 107, 1166–1173. 10.1182/blood-2005-06-2325. [PubMed: 16234360]

Pei S, et al., 2013. Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J. Biol. Chem 288, 33542–33558. 10.1074/jbc.M113.511170. [PubMed: 24089526]

Pollyea DA, Jordan CT, 2017. Therapeutic targeting of acute myeloid leukemia stem cells. Blood. 10.1182/blood-2016-10-696039.

Ran D, et al., 2009. Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp. Hematol 37, 1423–1434. 10.1016/j.exphem.2009.10.001. [PubMed: 19819294]

Reinisch A, et al., 2016. A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nat. Med 22, 812–821. 10.1038/nm.4103. [PubMed: 27213817]

Reinisch A, Chan SM, Thomas D, Majeti R, 2015. Biology and clinical relevance of acute myeloid Leukemia stem cells. Semin. Hematol 52, 150–164. 10.1053/j.seminhematol.2015.03.008. [PubMed: 26111462]

Rombouts EJ, Pavic B, Lowenberg B, Ploemacher RE, 2004. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 104, 550–557. 10.1182/blood-2004-02-0566. [PubMed: 15054042]

Rongvaux A, et al., 2014. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol 32, 364–372. 10.1038/nbt.2858. [PubMed: 24633240]

Saito Y, et al., 2010. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol 28, 275–280. 10.1038/nbt.1607. [PubMed: 20160717]

Saito Y, et al., 2016. Peripheral blood CD34+ cells efficiently engraft human cytokine knock-in mice. Blood. 10.1182/blood-2015-10-676452.

Sarry JE, et al., 2011. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammatac-deficient mice. J. Clin. Invest 121, 384–395. 10.1172/JCI41495. [PubMed: 21157036]

Schenk T, et al., 2012. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat. Med 18, 605–611. 10.1038/nm.2661. [PubMed: 22406747]

Schwitalla S, et al., 2013. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152, 25–38. 10.1016/j.cell.2012.12.012. [PubMed: 23273993]

Shackleton M, Quintana E, Fearon ER, Morrison SJ, 2009. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138, 822–829. 10.1016/j.cell.2009.08.017. [PubMed: 19737509]

Shlush LI, et al., 2017. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature 547, 104–108. 10.1038/nature22993. [PubMed: 28658204]

Skrtic M, et al., 2011. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20, 674–688. 10.1016/j.ccr.2011.10.015. [PubMed: 22094260]

Song WJ, et al., 1999. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat. Genet 23, 166–175. 10.1038/13793. [PubMed: 10508512]

Sood R, Kamikubo Y, Liu P, 2017. Role of RUNX1 in hematological malignancies. Blood 129, 2070–2082. 10.1182/blood-2016-10-687830. [PubMed: 28179279]

Suzuki N, et al., 2013. Generation of engraftable hematopoietic stem cells from induced pluripotent stem cells by way of teratoma formation. Mol. Ther. J. Am. Soc. Gene Ther 21, 1424–1431. 10.1038/mt.2013.71.

Taussig DC, et al., 2005. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106, 4086–4092. 10.1182/blood-2005-03-1072. [PubMed: 16131573]
Taussig DC, et al., 2010. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(−) fraction. Blood 115, 1976–1984. 10.1182/blood-2009-02-206565. [PubMed: 20053758]

Tavor S, et al., 2004. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res. 64, 2817–2824. 10.1158/0008-5472.can-03-3693. [PubMed: 15087398]

Terpstra W, et al., 1996. Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture. Blood 88, 1944–1950. [PubMed: 8822911]

Theocharides AP, et al., 2012. Disruption of SIRPalpha signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. J. Exp. Med 209, 1883–1899. 10.1084/jem.20120502. [PubMed: 22945919]

Thomas D, Majeti R, 2017a. Biology and relevance of human acute myeloid leukemia stem cells. Blood 129, 1577–1585. 10.1182/blood-2016-10-696054. [PubMed: 28159741]

Thomas D, Majeti R, 2017b. Biology and relevance of human acute myeloid leukemia stem cells. Blood. 10.1182/blood-2016-10-696054.

van Rhenen A, et al., 2005. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin. Cancer Res 11, 6520–6527. 10.1158/1078-0432.CCR-05-0468. [PubMed: 16166428]

Vetrie D, Helgason GV, Copland M, 2020. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat. Rev. Cancer 20, 158–173. 10.1038/s41568-019-0230-9. [PubMed: 31907378]

Vo LT, Daley GQ, 2015. De novo generation of HSCs from somatic and pluripotent stem cell sources. Blood 125, 2641–2648. 10.1182/blood-2014-10-570234. [PubMed: 25762177]

Volpato V, Webber C, 2020. Addressing variability in iPSC-derived models of human disease: guidelines to promote reproducibility. Dis. Model Mech 13 10.1242/dmm.042317.

Wahlster L, Daley GQ, 2016. Progress towards generation of human haematopoietic stem cells. Nat. Cell Biol 18, 1111–1117. 10.1038/ncb3419. [PubMed: 27723718]

Walter RB, Appelbaum FR, Estey EH, Bernstein ID, 2012. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 119, 6198–6208. 10.1182/blood-2011-11-325050. [PubMed: 22286199]

Wang YH, et al., 2020. A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients. Blood Adv. 4, 644–654. 10.1182/bloodadvances.2019001185. [PubMed: 32078680]

Wesely J, et al., 2020. Acute myeloid leukemia iPSCs reveal a role for RUNX1 in the maintenance of human leukemia stem cells. Cell Rep 31, 107688. 10.1016/j.celrep.2020.107688. [PubMed: 32492433]

Wunderlich M, et al., 2010. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 24, 1785–1788. 10.1038/leu.2010.158. [PubMed: 20686503]

Ye H, et al., 2016. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell 19, 23–37. 10.1016/j.stem.2016.06.001. [PubMed: 27374788]

Zeltner N, Studer L, 2015. Pluripotent stem cell-based disease modeling: current hurdles and future promise. Curr. Opin. Cell Biol 37, 102–110. 10.1016/j.celbi.2015.10.008. [PubMed: 26629748]

Zeng Z, et al., 2006. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol. Cancer Ther 5, 3113–3121. 10.1158/1535-7163.MCT-06-0228. [PubMed: 17172414]

Zeng Z, et al., 2009. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113, 6215–6224. 10.1182/blood-2008-05-158311. [PubMed: 18955566]

Zong H, et al., 2015. A hyperactive signalosome in acute myeloid leukemia drives addiction to a tumor-specific Hsp90 species. Cell Rep. 13, 2159–2173. 10.1016/j.celrep.2015.10.073. [PubMed: 26628369]
Leukemic cells from a patient with AML with aneuploidy, del7q and a subclonal $KRAS^{G12D}$ mutation were used to generate iPSCs. Upon directed hematopoietic differentiation these exhibited phenotypic and functional heterogeneity consistent with an LSC hierarchy.

*Fig. 1. The iLSC model.*